Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.31 |
| ▸ | GIPR | P48546 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23645343 | 0.88 | GCGR (0.30) | GCGRGIPR | |
| SCHEMBL23652755 | 0.88 | KDM4E (0.34) | RBP4KDM4EESR1POLB | |
| SCHEMBL23645421 | 0.83 | GRM2 (0.38) | RIPK1POLB | |
| SCHEMBL23652632 | 0.82 | FFAR4 (0.32) | RIPK1 | |
| SCHEMBL23645378 | 0.81 | RIPK1 (0.34) | KDM4ERIPK1POLB | |
| SCHEMBL23652798 | 0.80 | POLB (0.31) | RIPK1POLB | |
| SCHEMBL23653011 | 0.79 | KDM4E (0.33) | KDM4EESR1POLB | |
| SCHEMBL23645354 | 0.77 | KDM4E (0.32) | KDM4E | |
| SCHEMBL23645426 | 0.74 | KDM4E (0.35) | RBP4KDM4EESR1POLB | |
| SCHEMBL23645393 | 0.72 | POLB (0.37) | RIPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2025-09-23 | — | — | US | disclosed |
| CN-112689636-B | Novel heteroatom aromatic amide derivative and pharmaceutical agent containing same | 科研制药株式会社 | 2024-08-20 | — | — | CN | disclosed |
| EP-3851436-B1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2024-06-12 | — | — | EP | disclosed |
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-3851436-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2021-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | GCGR 2395/4885GIPR 2124/4885RBP4 3273/4885 |
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | GCGR 1789/4885GIPR 1751/4885RBP4 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.